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Hepatic　 expression　 of　 hepatitis　 B　 core　 antigen(HBcAg)and　 β2-
microglobulin　 (β2-MG) was　 studied　 in　 42　 patients　 with　 liver
biopsy-proven chronic hepatitis B; 31 were hepatitis Be antigen 
(HBeAg)-seropositive and 11 were anti-HBeAg antibody (anti-
HBe)-seropositive at base line. The degrees of expression of both
HBcAg　 and β2-MG　 at　base line　 were　 significantly　 higher　 in　HBeAg-
seropositive patients than in anti-HBe-seropositive patients (p < 0.001 
and p < 0.001, respectively). During two-year-follow-up, 14 of 31 
HBeAg-seropositive patients were seroconverted to anti-HBe 
(HBe-seroconversion). When the base line hepatic expression of
HBcAg　 and　 β2-MG　 was　 compared　 between　 the　 patients　 with　 sub-
sequent HBe-seroconversion and the non-soroconverted patients,
β2-MG　 expression　 on　 hepatocytes　 in　 the　 patients　 with　 subsequent
HBe-seroconversion was significantly more intense than that in the 
non-soroconverted patients (p < 0.025). In contrast, the degrees of 
HBcAg expression at base line were not different between the two
groups.　 These　 results　 suggest　 that　 the　hepatic　 expression　 of β2-MG　 as
well as that of HBcAg correlates with the serum level of HBeAg and
that　 the　 increased　 expression　 of β2-MG　 is　followed　 by　 HBe-sero-
conversion in patients with chronic hepatitis B.
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Introduction 
The hepatocyte damage induced by hepatitis B virus 
(HBV) infection is not due to a direct viral cytopathic 
effect, but mainly due to T cell-mediated cytotoxicity 
against the HBV-associated antigen expressed on the in-
fected hepatocytes.'2'3) Adherence of lymphocytes to the 
infected hepatocytes is thus necessary for the immune 
response. The process of cell to cell adhesion is mediated 
by antigenic determinants displayed in conjunction with the 
major histocompatibility complex (MHC) products on the 
infected hepatocyte.4) 
 The hepatic expression of HBV nucleocapside antigens 
such as hepatitis B core antigen (HBcAg) and hepatitis Be 
antigen (HBeAg) was reported to be not only a marker of 
HBV replication but also a major target antigen for T 
cell-mediated cytotoxicity in chronic hepatitis B."7 The 
serum level of HBeAg is also clinically used as a marker of 
HBV replication." Previous studies demonstrated that the 
seroconversion from HBeAg to anti-HBe (HBe-serocon-
version) occurs spontaneously in the patients with chronic 
hepatits B, resulting in the decrease in liver inflammation 
activity." "I Several groups showed that bridging hepatic 
necrosis during acute exacerbation was associated with 
HBe-seroconversion.$• 11) However, little is known about the 
relation of HBe-seroconversion with the hepatic expression 
of the HBV-related antigens or the MHC class 1 products. 
 In the present study, the hepatic expression of HBcAg 
and /32-microglobulin (/32-MG), a subunit of the HLA 
class 1 products,") was studied in 42 patients with a biopsy-
proven chronic hepatitis B in order to clarify the associ-
ation of expression of HBcAg and X32-MG with HBe-
seroconversion.
Materials and Methods 
Fifty-five liver biopsy specimens from 42 patients with 
chronic hepatitis B were used in this study. All the patients 
were hepatitis B surface antigen-seropositive for more than 
2 years and had biopsy-proven chronic hepatitis. The 
patients who had the antibody to hepatitis delta virus or 
hepatitis C virus were excluded from this study, as were the 
patients with drug or alcohol abuse. These 42 patients were 
followed for, at least, 2 years after receiving the first liver 
biopsies. The histological degrees of chronic hepatitis in 
the patients were based on the international classification") 
(Table 1). HBe-seroconversion occurred spontaneously in
Table 1. Summary of the patients.
                   HBeAg (+) Anti-HBe (+) 
male:female 27:4 9:2 
age (mean ± SD) 31.7 ± 6.5 y. o 29.0 ± 4.0 y. o 
Histological diagnosis 
  CPH 3 6 
  CAH2A 13 5 
  CAH2B 15 0 
CPH: chronic persistent hepatitis 
CAH2A: chronic active hepatitis with moderate inflammatory 
activity 
CAH2B: chronic active hepatitis with severe inflammatory 
activity
14 of 31 HBeAg-seropositive patients during follow-up, 
while 17 patients remained HBeAg-seropositive. The sec-
ond liver biopsy specimens were obtained from 10 of the 
14 HBe-seroconverted patients after HBe-seroconver-
sion.Three of 17 non-seroconverted patients also allowed 
to receive the second liver biopsies at intervals of more 
than one year. 
 Each specimen was fixed in 10% formaldehyde solution, 
embedded in paraffin and used for routine histology. For 
immunohistochemistry, deparaffinized sections were 
stained by the Biotin-Streptavidin complex method (Bio 
Genex Labo., U. S. A.). In brief, the sections were reacted 
for 30min at room temperature with rabbit polyclonal 
anti-human /32-MG antibody (DAKO; working dilutions = 
1:500) or rabbit polyclonal anti-HBcAg antibody (DAKO;
working dilutions = 1:200). After washing with phosphate 
buffered saline (PBS), pH7.4, three times, the sections 
were reacted for 20min with biotinylated goat anti-rabbit 
immunoglobulin G, followed by incubation for another 
20min with peroxidase-conjugated streptavidin, and 
washed in PBS, pH7.4. The reaction products were visu-
alized by incubation for 10min in 0.61 M Tris HCI buffer, 
pH7.4, containing 0.05% diaminobenzidine and 0.01% H2 
02. The intensity of the hepatic expression of 82-MG and 
HBcAg was graded independently by three observers 
without the prior knowledge of the clinical data. 
 Expression of 82-MG on hepatocytes was graded as 
follows; (-) negative, (+) weakly positive, (++) stongly 
positive. The representative cases are displayed in Fig. 1. 
The hepatic expression of HBcAg was also scored semi-
                                Fig. 1. Expression of X32-MG on hepatocytes. 
The staining intensity of 62-MG on hepatocyte membrane was negative (A), weakly positive (B) and strongly positive (C). (x 200)
quantitatively as follows; (-) negative, (+) scattered distri-
bution of hepatocytes containing HBcAg in a few lobules, 
(++) scattered of diffuse distribution of hepatocytes con-
taining HBcAg in more than a few lobules (Fig. 2). 
 Statistical analyses were carried out using the chi-square 
test. P values < 0.05 were considered statistically signif-
icant.
Results 
Difference in the hepatic expression of HBcAg and X32-MG 
between HBeAg-seropositive patients and anti-HBe-
seropositive patients 
The degree of HBcAg expression in 29 of 31 HBeAg-
seropositive patients was more than I+, whereas expression 
of HBcAg was negative in 10 of 11 anti-HBe-seropositive 
patients. The difference was statistically significant (p < 
0.0001). The intensity of expression of 82-MG in HBeAg-
seropositive patients was also significantly higher than that 
in anti-HBe-seropositive patients (p < 0.01) (Table 2).
                                 Fig. 2. The hepatic expression of HBcAg. 
Score of the staining intensity was described in Materials and Methods. Negative (A), scattered distribution of hepatocytes containing H
BcAg in a few of the lobules (B), Scattered or diffuse distribution of hepatocytes containing HBCAg in more than a few of the lobules 
(C). (x 200)
Table 2. Difference of the hepatic expression of 82-MG and 
       HBcAg between HBeAg-seropositive patients and
        anti-HBe-seropositive patients.
                      X32-MG HBcAg 
                          expression expression
                         - + ++ - + ++
Serum HBeAg (+) n = 31 1 12 18 2 10 19 
Serum HBeAg (-) n = 11 0 11 0 10 1 0 
p-value p < 0.01 p < 0.001 
Statistical analysis was carried out using chi-square test.
When the changes in the hepatic expression of HBcAg and 
,82-MG before and after HBe-seroconversion were ana-
lyzed in the 10 HBe-seroconverted patients, expression of 
HBcAg and 62-MG became less intense after HBe-
seroconversion in 9 and 6, respectively, of the 10 serocon-
verted patients; in contrast, expression of 62-MG showed 
no interval changes in all of the three non-seroconverted 
patients and expression of HBcAg increased in two of the 
three patients (Fig. 3).
Fig. 3. Changes in the hepatic expression of 82-MG and HBcAg 
before and after HBe-seroconversion. 
®: HBeAg seropositive state 
0 : anti-HBe seropositive state
Association of the hepatic expression of HBcAg and 
,Q2-MG with subsequent HBe-seroconversion 
Expression of HBcAg and 82-MG at base line was com-
pared between 14 patients with subsequent HBe-
seroconversion and 17 non-seroconverted patients (Table 
3). The mean age and the sex distribution were. not differ-
ent between the two groups. The degree of X32-MG expres-
sion at base line was significantly more intense in the 
patients with subsequent HBe-seroconversion than in the 
non-seroconverted patients (p < 0.025), whereas the degree
Table 3. Association of the hepatic expression of 82-MG and 
        HBcAg with subsequent HBe-seroconversion.
                      X32-MG HBcAg 
                          expression expression
                         - + ++ - + ++
HBeAg (+) -~ Anti-HBe (+) 
 male:female = 12:2 0 2 12 1 6 7 
  age =33.1 ± 6.3y. o. 
HBeAg (+) - HBeAg (+) 
 male:female = 15:2 1 10 6 1 4 12 
  age = 30.5 ± 6.2 y. o. 
p-value p < 0.025 p > 0.25 
Statistical analysis was carried out using chi-aquare test.
of HBcAg expression was not different between the two 
groups (p > 0.05).
Discussion 
The hepatic expression of HBcAg and the MHC class 1 
products is closely associated with liver inflammation ac-
tivity in chronic hepatitis B.4.1447) In this study, the hepatic 
expression of HBcAg and 82-MG, a topographic distri-
bution of which is similar to the MHC class 1 products,"' 
was analyzed in 42 patients with chronic hepatitis B. The 
degree of the hepatic expression of HBcAg in HBcAg-
seropositive patients was significantly higher than in anti-
HBe-seropositive patients. When expression of HBcAg 
was studied before and after HBe-seroconversion in HBe-
seroconverted patients, HBcAg expression was clearly re-
duced after HBe-seroconversion. Since the serum level of 
HBeAg is associated with HBV replication in hepatocytes, 
these results indicate that the hepatic expression of HBcAg 
closely correlates with HBV replication. The intensity of 
the hepatic expression of )32-MG in HBcAg-seropositive 
patients was also significantly higher than that in anti-
HBe-seropositive patients. Several studies showed that 
expression of the MHC class 1 products on hepatocytes 
was associated with the serum aminotransferase level, but 
not with the serum level of HBeAg.19' The discrepancy 
between the previous and the present results seems to be, in 
part, due to the patients studied, because the activity of 
liver inflammation in HBeAg-seropositive patients was 
much higher than that in anti-HBe-seropositive patients in 
our study. Chu et a1.16' also found that the hepatic expres-
sion of the MHC class 1 products was associated with viral 
replication and histological activity in chronic hepatitis B, 
with the most intense display in the patients with HBeAg-
seropositive chronic active hepatitis. 
  HBe-seroconversion occurs spontaneously in chronic 
hepatitis B, resulting in normalization of the serum amino-
transferase level and the histological improvement.', 10'
Fattovich et al. demonstrated that approximately 60% of 
HBeAg-seropositive patients with chronic hepatitis B were 
seroconverted to anti-HBe during a mean follow-up period 
of 5 years, and that liver inflammation was repressed in 
90% of the patients after HBe-seroconversion.20' Several 
workers reported similar results."-"' However, it remains 
obscure how the hepatic expression of the HBV-related 
antigens or the MHC class 1 products is associated with 
HBe-seroconversion. Therefore, we focused on the rela-
tionship between their expression and HBe-seroconversion. 
In this study, the base line intensity of 62-MG expression 
was significantly higher in the patients with subsequent 
HBe-seroconversion than in the non-seroconverted pa-
tients, but the degree of HBcAg expression was not differ-
ent between the two groups at base line. These results 
suggest that the increased expression of a 2-MG on hepato-
cytes but not the increased HBV replication is followed by 
HBe-seroconversion. HBe-seroconversion is thought to 
result from the enhanced immune response of the host to 
HBV. In fact, some investigators showed that acute exacer-
bation in chronic hepatitis B was frequently found during 
HBe-seroconversion with the increased expression of the 
MHC class 1 products on hepatocytes.16.19) These findings 
agree well with our results. 
  Recently, interferon has been used clinically in the treat-
ment of chronic hepatitis B. Although interferon directly 
suppresses the replication of HBV in hepatocytes, the 
clinical results of interferon therapy cannot be explained 
only by the anti-replicative effects of interferon on 
HBV.21.221 Since interferon induces the hepatic expression 
of the MHC class 1 products in vitro and in vivo,23' 1' it is 
possible that clinical effects of interferon are mediated by 
the increased expression of the MHC class 1 probucts on 
hepatocytes in chronic hepatitis B.
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